Axsome Therapeutics develops innovative treatments for central nervous system (CNS) conditions, including depression, Alzheimer's disease agitation, migraine, narcolepsy, and fibromyalgia. The company is focused on bringing new therapies to patients.

Axsome Therapeutics

HSTS

DNSSEC

IPv6

Google

Google Cloud

CrUX Top 50m

CloudFront

Microsoft

Common Name Invalid

CrUX Top 10m

Chief Executive Officer

Herriot Tabuteau

Chief Operating Officer

Mark Jacobson

Chief Financial Officer

Nick Pizzie

Marketing and Product

Brad Raudabaugh

EVP, Legal & Compliance

Hunter Murdock

Executive Vice President, Product Strategy

Kevin Laliberte

Senior Vice President, Commercial and Business Development

Lori Englebert

Vice President Program Management

Thomas Cavanagh

Specialty Account Manager

Adam Edlefson, MBA

Sales and Support

Alecia Partridge

Hrishi Dixit

Robert Niecestro

VP, Head of Regulatory Affairs

Biotechnology Companies With More Than $100M in Revenue

New York Companies With More Than 10 Employees (Top 10K)

Northeastern US Public Companies With More Than $1M in Revenue

East Coast Public Companies With More Than 50 Employees

Axsome Therapeutics is a biopharmaceutical company developing novel therapies for the treatment of pain and other neurological diseases. By focusing on this therapeutic area, Axsome is addressing growing markets where current treatment options are limited or inadequate. Axsome has a balanced portfolio of clinical development stage as well as research stage products.

Axsome Therapeutics aims to become a fully integrated biopharmaceutical company that develops and commercializes differentiated products which increase the armamentarium of caregivers and improve the lives of patients. While the focus of the company is on developing its internally derived product candidates, Axsome also evaluates potential in-licensing opportunities to supplement its current portfolio.

Post-IPO Equity - Axsome Therapeutics

Venture Round - Axsome Therapeutics

Debt Financing - Axsome Therapeutics

New York

United States

North America

Axsome reports positive Phase 3 data for AXS-12 for narcolepsy (NASDAQ:AXSM)

Axsome Therapeutics (AXSM) Announces AXS-12 Achieves Primary Endpoint

Axsome moves toward NDA filing for narcolepsy drug following positive Phase 3 data

Biotech Alert: Searches spiking for these stocks today

Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Axsome Therapeutics GAAP EPS of -$1.34 beats by $0.07, revenue of $104.76M beats by $6.69M (AXSM:NASDAQ)

Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024

Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.

Axsome Therapeutics COO Sells Shares Worth Over $4 Million

Axsome Therapeutics reports Q2 EPS ($1.67), consensus ($1.33)

An extended-release tablet combining dextromethorphan hydrobromide and bupropion hydrochloride for the treatment of major depressive disorder.

A tablet containing solriamfetol, used to improve wakefulness in adults with excessive daytime sleepiness due to obstructive sleep apnea or narcolepsy.

An investigational NMDA receptor antagonist with multimodal activity, being developed for Alzheimer's disease agitation and smoking cessation.

An investigational medicine combining MoSEIC meloxicam and rizatriptan, being developed for the acute treatment of migraine.

An investigational norepinephrine reuptake inhibitor, reboxetine, being developed for the treatment of narcolepsy.

India

Asia

Turkey

Europe

Canada

Indonesia

HTML5

Amazon EC2

Google Fonts

Google Drive

Apache Server

Wordpress

Comodo PositiveSSL Certificates

Modernizr

Google Analytics

Starfield SSL

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Axsome Therapeutics, Inc.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Dec 5, 2024 1:09 AM	d9aed683
public peers	general	Oct 23, 2024 5:17 AM	e7894715
news daily refresh	general	Dec 31, 2024 6:00 PM	e71f619c
news processing daily refresh	general	Dec 20, 2024 4:48 PM	3d8e80e4
news impact assignment daily	general	Dec 20, 2024 6:29 AM	7f321197
news processing basic	general	Dec 4, 2024 2:41 PM	875b7869
company summary	general	Dec 20, 2024 6:42 AM	e0f63fae
signals	general	Oct 23, 2024 5:17 AM	bc2913b5
crunchbase trigger	general	Nov 27, 2024 12:50 PM	ade195bc
crunchbase profile	general	Nov 28, 2024 8:44 AM	923e6a03
li profile	general
translate crunchbase fundingrounds	general	Nov 28, 2024 9:13 AM	4b3eb885
peers	general	Oct 23, 2024 5:17 AM	9a36329e
news basic	general	Dec 4, 2024 2:13 PM	67eef475
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:AXSOME

Axsome Therapeutics

Last Close

98.19

22/11 21:00

Market Cap

3.92B

Beta: -

Volume Today

425.39K

Avg: -